Business Context and Reporting Period
This Form 8-K is a current report filed by Enochian Biosciences Inc. (not Lunai Bioworks Inc.) on June 23, 2023, regarding events occurring on June 22, 2023. The filing addresses the status of the Company's 2023 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
- Meeting Adjournment: The 2023 Annual Meeting of Stockholders, originally scheduled for June 22, 2023, was adjourned due to a lack of quorum.
- New Meeting Date: The meeting has been reconvened for Friday, July 21, 2023, at 12:00 p.m. Eastern Time.
- Format: The reconvened meeting will be held virtually.
- Proposals: No changes have been made to the proposals to be voted on by stockholders.
Outlook, Risks, and Management Commentary
Management is actively soliciting additional votes to achieve the required quorum, defined as a majority of the outstanding shares of Common Stock. The Company has engaged Alliance Advisors, LLC, a proxy solicitation firm, to assist in this effort. Stockholders who have already voted do not need to recast their votes, as previously submitted proxies will be voted at the adjourned meeting unless revoked. The Company urges stockholders of record as of May 10, 2023, who have not yet voted, to do so before the new meeting date.
Key Facts for Investor Verification
- Verify the specific proposals listed in the definitive proxy statement filed on May 15, 2023, as these remain unchanged.
- Confirm the virtual registration deadline of 11:59 PM EST on July 20, 2023, to attend the reconvened meeting.
- Review the 2022 Annual Report on Form 10-K for the most recent financial data, as this 8-K contains no financial figures.
- Monitor the Company's ability to secure a quorum for the July 21 meeting to ensure the proposed corporate actions can proceed.